IASLC 2023

IASLC WCLC 2023 Conference - Tagrisso, a targeted therapy, combined with chemotherapy, extended the median progression-free survival by nearly 9 months in patients with EGFR-mutated advanced lung cancer, according to the FLAURA2 Phase III trial.

Tagrisso-chemo combo delays EGFR NSCLC progression by 9 months in first-line (IASLC WCLC 2023 Conference)

Anika Sharma

Against the formidable challenge of non-small cell lung cancer (NSCLC), AstraZeneca’s Tagrisso (osimertinib), when partnered with chemotherapy, has unveiled remarkable ...

IASLC WCLC 2023 Conference - Fasenra, a biologic medicine, met the primary endpoint of inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and severe inflammatory disease.

Fasenra, a new treatment for EGPA, achieved remission in Phase III trial (IASLC WCLC 2023 Conference)

Anika Sharma

The MANDARA Phase III trial has shed new light on the effectiveness of AstraZeneca’s Fasenra (benralizumab). Unveiling favorable high-tier outcomes, ...

TROPION-Lung04, datopotamab deruxtecan, Dato-DXd, Imfinzi, NSCLC, International Association for the Study of Lung Cancer, IASLC 2023, Immunotherapy, antibody-drug conjugate

Datopotamab Deruxtecan + Imfinzi Transform First-Line NSCLC Treatment in TROPION-Lung04 Trial

Anika Sharma

The TROPION-Lung04 Phase Ib trial has unveiled highly promising results. The trial showcases the potential of datopotamab deruxtecan (Dato-DXd), in ...